EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug

EyePoint filed a lawsuit in Middlesex County, Massachusetts alleging Ocular Therapeutix spread false or misleading statements about EyePoint and its pipeline drug Duravyu, seeking an injunction, public retraction, monetary damages and legal fees. Duravyu is in late-stage trials for wet AMD and diabetic macular edema with wet AMD data expected mid-2026, while Ocular’s Axpaxli recently met the primary endpoint in a late-stage wet AMD trial versus Regeneron’s Eylea. The dispute creates near-term reputational and commercial risk for both companies and could move either stock by a few percent ahead of the legal outcome and upcoming trial readouts.

Analysis

The legal dispute injects asymmetric information and timing risk into a biotech duel whose commercial outcome already hinges on a single late-stage data readout ~15 months out. Practically, litigation often delays partner diligence and licensing checks by 3–9 months and raises due-diligence costs that acquirers/partners price as a 20–40% haircut to pre-litigation valuations, particularly for small-cap ophthalmology developers with limited cash runways.

Near-term market action will be driven by binary legal milestones (preliminary injunctions, discovery leaks, and press statements) over the next 30–90 days; these typically produce 15–35% intraday moves in either direction for thinly traded names. The real operational risk is second-order: plaintiff-focused management teams divert executive time into legal strategy, which commonly slows enrollment and can translate into 6–12 month slippages in clinical timelines — a material cash-burn and re-rate accelerator for both sides.

A rational arbitrage is to treat the situation as a volatility event rather than pure clinical differentiation. If the plaintiff can obtain a rapid favorable court action, the plaintiff’s equity can re-rate >50%; conversely, an adverse early ruling or damaging discovery can fast-track a 40%+ downside for the accused party. Monitor cash runway, board-level covenant waivers, and any changes in CRO/clinical sites as high-signal indicators that will move price ahead of the clinical readout.

Key Decisions for Investors

• Pair trade (1–3 month window): Long OCUL 3–6 month ATM calls (buy), funded by short EYPT 3–6 month ATM calls — targets: +40% on OCUL calls if favorable legal headlines within 60 days; risk: if adverse ruling, cap loss at 25% of notional. Size 1–2% net portfolio exposure.
• Event-driven short: Buy EYPT 1–3 month puts or outright short shares if share gap up on rhetoric without supportive cash/runway update — set stop-loss at +20% and target 30–50% downside if legal/operational delays are confirmed. Max position 1% of NAV.
• Volatility sell/buy: Sell near-term implied volatility on the defendant if IV spikes >60% of historical (collect premium) and buy longer-dated protective puts (12–18 months) to hedge clinical-timeline risk; expected carry if no adverse legal outcome within 3 months.
• Monitor triggers (no position until one hits): court ruling or SEC/partner comment — if plaintiff obtains injunctive relief, rotate into plaintiff equity (size up to 2% NAV) with a 6–12 month horizon to mid-2026 data; if discovery reveals material harm to plaintiff’s claims, go net-short the plaintiff name.
• Avoid thematic drift: do not increase exposure to unrelated small-cap biotech names on headline momentum. Keep aggregate litigation-exposed biotech exposure <5% of hedge fund equity risk budget to limit crowding and idiosyncratic tail risk.